Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit

Table 1 Worldwide prevalence of Meropenem-resistant Acinetobacter Baumannii, n %

Continent	Country	Prevalence	Site of infection	Ref.
Africa	Uganda	81.25	Mix	[44]
America	Brazil	22.8-94.2	Mix	[42,59]
	Canada	4.4	Mix	[41]
	French Guiana	16.2	Mix	[60]
	Mexico	56.6	Mix	[61]
	Uruguay	100	Mix	[40]
	United States	61.2-74.2	Mix	[26]
Asia	China	76.7-91.8	Mix	[42,43]
	India	65.2	VAP	[62]
	Indonesia	16.7-68	Mix	[50,63]
	Iran	53.8-94.5	Mix	[64,65]
	Jordan	88.2	Mix	[66]
	Kazakhstan	44.4	Mix	[67]
	Korea	55.8-91.8	Mix	[52,53]
	Saudi Arabia	6.2-52.6	Mix	[68,69]
	Taiwan	50.7	Mix	[70]
	Thailand	40.5-69	Mix	[71,72]
	Vietnam	84	VAP	[73]
Europe	Germany	431	Mix	[74,75]
	Greece	58.9	Mix	[76]
	Italy	70	VAP	[77]
	Lithuania	30	VAP	[78]
	Poland	74.9-92.3	Mix	[54,55]
	Romania	86.5	Mix	[39]
	Russia	38-67.5	Mix	[79,80]
	Serbia	82	HAC	[81]
		85.3	VAP
	Spain	86.05	Mix	[82]
	Switzerland	37	Mix	[51]

¹Authors used carbapenems other than Meropenem or do not specify the carbapenem tested.

VAP: Ventilator-associated pneumonia; HAC: Hospital-acquired condition; Mix: More than one infection site or aggregated data about them.